# 服用該標靶藥物的患者存活期幾乎是接受標準化療患者的兩倍，這是胰臟癌領域前所未見的結果。

*biotech · news · 2026-05-31 · STAT*

## Key points

- 接受實驗性藥物 daraxonrasib 治療的患者存活期幾乎是標準化療的兩倍。
- 這是胰臟癌治療中首次觀察到如此顯著的存活期改善。
- daraxonrasib 的臨床結果於四月在亞利桑那大學癌症中心公布。
- 胰臟癌專家 Rachna Shroff 表示，這項發現是她 16 年職業生涯中前所未有的。

CHICAGO — Rachna Shroff, a physician and pancreatic cancer expert, was seeing patients at the University of Arizona Cancer Center in April when she heard the striking clinical results about an experimental pill called daraxonrasib. Patients taking the targeted drug lived nearly twice as long as patients offered standard chemotherapy — an outcome never seen before in the pancreatic cancer field. “Having treated pancreatic cancer for 16 years, I actually started crying in the clinic,” Shroff said at a media briefing. “This is such an incredibly impactful study for our patients.” Advertisement

**Countries:** United States

[Read the full story on STAT](https://www.statnews.com/2026/05/31/pancreatic-cancer-daraxonrasib-revolution-medicines-results-asco-2026/)

---

Canonical: https://newsio.io/zh-TW/n/7155e8c7-8942-486e-8c56-bc5a0cddeef4/
Summarized by Newsio from STAT. https://newsio.io/how-it-works